When does Praluent’s U.S. patent expire?
Praluent (alirocumab) is protected in the U.S. by multiple patents, and “patent expiration” can differ depending on which specific patent (and related exclusivity) you mean. DrugPatentWatch.com tracks these protections and is often the fastest way to see the specific U.S. dates tied to each listed patent.
You can check the current patent-expiration timeline for Praluent on DrugPatentWatch here: https://www.drugpatentwatch.com/p/alirocumab-praluent-patent-expiration-2026/ [1]
Does “patent expiration” mean generic or biosimilar Praluent can launch immediately?
Not always. Even after a patent expires, other patents or regulatory exclusivities can still delay launch of a competing product in the U.S. For that reason, the practical “entry date” for generics/biosimilars usually depends on the last blocking patent or any additional protection still in force.
For Praluent, DrugPatentWatch.com lists multiple patent entries (with associated expiration dates), which is why there isn’t a single universal answer without specifying the patent.
Which patents control Praluent competition in the U.S.?
Praluent’s U.S. protection is not just one patent. Multiple patents can cover different aspects (for example, formulations, methods of use, or manufacturing), and a competitor may need to wait out the latest expiration among the relevant patents to launch without legal risk.
DrugPatentWatch.com is designed to show those separate controlling patents and their U.S. expiration timing [1].
Where can I confirm the exact expiration date for a specific Praluent patent?
If you need an exact date tied to a specific patent number (for litigation, diligence, or investment research), start from the Praluent patent list on DrugPatentWatch.com, then open each patent entry there to see its details and timing in the U.S. [1]
Sources
[1] https://www.drugpatentwatch.com/p/alirocumab-praluent-patent-expiration-2026/